Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27367847 | 1.00 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL20067101 | 1.00 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL128692 | 1.00 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL19588665 | 1.00 | EPHX2 (0.38) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL30985685 | 0.98 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL31296126 | 0.98 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| Iodide SCHEMBL237045 | 0.98 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL30454549 | 0.98 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| SCHEMBL31373110 | 0.98 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D | |
| Bromide SCHEMBL28905083 | 0.98 | EPHX2 (0.37) | EPHX2HSD11B1KMT2ASMN1; SMN2GRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105518-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NTRK2, NGF | EPHX2 1678/4885HSD11B1 4718/4885KMT2A 3380/4885 |
| US-10556900-B2 | TrkA kinase inhibitors, compositions and methods thereof | NGFR, NTRK2, NGF | EPHX2 1678/4885HSD11B1 4718/4885KMT2A 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.